■口腔扁平苔藓(OLP)是一种相对常见的以疼痛和炎症为特征的慢性T细胞介导的疾病。丙酸氯倍他索(CLO)是治疗OLP的一线药物。Meta分析旨在评估CLO治疗OLP患者的有效性和安全性。
■PubMed,Embase和WebofScience从截至2023年8月的数据库开始日期进行了系统搜索。没有语言或发布日期的限制。我们感兴趣的结果如下:临床体征和/或症状的改善,总病变大小,复发和不良事件。
■本研究包括总共17项评估CLO效果的RCT。结果显示,CLO和其他治疗之间的临床评分(WMD=0.14,95%CI:-0.39,0.66;p=0.609)和疼痛评分(WMD=0.17,95%CI:-0.44,0.79;p=0.582)没有显着差异。然而,CLO和其他治疗组的临床疗效(RR=1.61,95%CI:1.17,2.22;p=0.003)和症状改善(RR=1.80,95%CI:1.17,2.77;p=0.008)有显著差异.此外,CLO治疗后总病灶大小显著减少(WMD=-0.58,95%CI:-1.03,-0.13;p=0.011).此外,与其他疗法相比,CLO显示不良事件(RR=1.46,95%CI:0.86,2.50;p=0.161)和复发(RR=1.56,95%CI:0.66,3.71;p=0.314)的发生率无统计学意义。
■这项对17项随机临床试验的系统评价和荟萃分析支持CLO作为OLP患者的有效治疗方案的长期应用。
UNASSIGNED: Oral lichen planus (OLP) is a relatively common chronic T cell-mediated disease characterized by pain and inflammation. Clobetasol propionate (CLO) is the first-line drug in the treatment of OLP. The meta-analysis aimed to evaluate the efficacy and safety of CLO for treating patients with OLP.
UNASSIGNED: PubMed, Embase and Web of Science were systematically searched from the database inception date up to August 2023. There were no restrictions on language or date of publication. The outcomes of our interest were as follows: improvement of clinical signs and/or symptoms, total lesion size, relapse and adverse events.
UNASSIGNED: A total of 17 RCTs evaluating the effects of CLO were included in this study. The results revealed no significant difference in the clinical score (WMD = 0.14, 95% CI: -0.39, 0.66; p = 0.609) and pain score (WMD = 0.17, 95% CI: -0.44, 0.79; p = 0.582) between CLO and other treatments. However, clinical resolution (RR = 1.61, 95% CI: 1.17, 2.22; p = 0.003) and symptoms improvement (RR = 1.80, 95% CI: 1.17, 2.77; p = 0.008) were significantly different between CLO and other treatments. Moreover, there was a significant reduction in the total lesion size with CLO treatment (WMD = -0.58, 95% CI: -1.03, -0.13; p = 0.011). In addition, CLO showed no statistical incidence of adverse events (RR = 1.46, 95% CI: 0.86, 2.50; p = 0.161) and relapse (RR = 1.56, 95% CI: 0.66, 3.71; p = 0.314) than other therapies.
UNASSIGNED: This systematic review and meta-analysis of 17 randomized clinical trials supported the long-term application of CLO as an effective regimen in OLP patients.